# **ASTHMA**

Dr MAHBOUBEH MANSOURI
ASSOCIATE PROFESSOR OF SHAHID BEHESHTI UNIVERSITY OF MEDICAL
SCIENCES

#### **PATHOGENESIS**

- Inflammation in asthmatic airways: Inflammatory cells (mast cells, eosinophils, T lymphocytes, neutrophils), chemical mediators (histamine, leukotrienes, platelet-activating factor, bradykinin), and chemotactic factors (cytokines, eotaxin)
- Inflammation ➤ airway hyperresponsiveness
- Bronchoconstriction, ↑mucus production in the lungs, influx of inflammatory cells into the airway tissue, and epithelial cell denudation.
- Chronic inflammation ➤ to airway remodeling :proliferation of extracellular matrix proteins +vascular hyperplasia ➤ progressive loss of pulmonary function

# Epidemiology

- Asthma is the most common chronic disease of childhood
- affecting nearly 7 million children younger than 18 years of age in US
- In adults, females are more likely than males to have asthma, but in children the reverse is true.
- Among children less than 18 years of age, asthma prevalence increased by 1.4% per year.
- For children, the death rate is 2.5 per million.

#### CLINICAL SYMPTOMS

- In Children: coughing, wheezing, shortness of breath, exercise intolerance, or chest tightness.
- The history should elicit :the frequency, severity, and precipitating factors as well as a family history of asthma and allergy
- Common exacerbating factors include viral infections, exposure to allergens and irritants (e.g., smoke, air pollution, strong odors, fumes), exercise, emotions, and change in weather/humidity.
- Nocturnal symptoms are common.
- Rhinosinusitis, gastroesophageal reflux, and aspirin can aggravate asthma.
   Treatment of these conditions may lessen the frequency and severity of asthma.

### ACUTE ASTHMA SYMPTOMS

- tachypnea, tachycardia, cough, wheezing, and a prolonged expiratory phase may be present.
- Physical findings may be subtle,
- As the attack progresses, cyanosis, diminished air movement, here is poor aeration from airway
- retractions, agitation, inability to speak, tripod sitting position, diaphoresis, and pulsus paradoxus (decrease in blood pressure of >15 mm Hg with inspiration)
- Physical examination may show evidence of other atopic diseases such as eczema or allergic rhinitis.

# Laboratory and Imaging Studies

- no single test or study can confirm the diagnosis of asthma
- Many elements contribute to establishing the diagnosis the most important is clinical history
- pulmonary function (spirometry) aid in the diagnosis and direct the treatment of asthma.
- Children older than 5 years of age can usually perform spirometry maneuvers
- For younger children peak flow or, a therapeutic trial of controller medications aids in the diagnosis of asthma

# Laboratory and Imaging Studies

- Allergy skin testing should be included in the evaluation of all children with
- persistent asthma but not during an exacerbation of symptoms. Positive skin test
- results, identifying sensitization to aeroallergens (e.g., pollens, mold, dust mite,
- pet dander), correlate strongly with bronchial allergen provocative challenges. In
- vitro serum tests, such as enzyme-linked immunosorbent assay (ELISA), are
- generally less sensitive in defining clinically pertinent allergens, are more
- expensive, and require several days for results, compared to several minutes for
- skin testing

# Laboratory and Imaging Studies

- An x-ray should be performed with the first episode of asthma or with recurrent episodes of undiagnosed cough or wheeze to exclude anatomic abnormalities.
- Repeat chest x-rays are not needed with new episodes unless there is fever (suggesting pneumonia) or localized findings on physical examination.
- exhaled nitric oxide
- analysis and quantitative analysis of expectorated sputum for eosinophilia.

#### Differential Diagnosis of Cough and Wheeze in Infants and Children

UPPER AIRWAY	OBSTRUCTION INVOLVING	OBSTRUCTION INVOLVING	OTHER
DISEASES	LARGE AIRWAYS	SMALL AIRWAYS	
Allergic rhinitis Sinusitis	Tracheal or bronchial foreign body Paradoxical vocal fold motion Vascular rings or laryngeal webs Enlarged lymph nodes or tumor	Viral bronchiolitis or obliterative bronchiolitis Cystic fibrosis Bronchopulmonary dysplasia (chronic lung disease of prematurity)	Recurrent cough not caused by asthma (infection, habit cough, postnasal drip) Aspiration from swallowing mechanism dysfunction or gastroesophageal reflux disease

# Mnemonic of Causes of Cough in the First Months of Life

- C—Cystic fibrosis
- R—Respiratory tract infections
- A—Aspiration (swallowing dysfunction, gastroesophageal reflux, tracheoesophageal fistula, foreign body)
- D—Dyskinetic cilia
- L—Lung and airway malformations (laryngeal webs, laryngotracheomalacia, tracheal stenosis, vascular rings and slings)
- E—Edema (heart failure, congenital heart disease)

- Allergic bronchopulmonary aspergillosis is a hypersensitivity reaction to
- antigens of the mold Aspergillus fumigatus. It occurs primarily in patients with
- steroid-dependent asthma and in patients with cystic fibrosis.

#### **Controlling Factors Contributing to Asthma Severity**

MAJOR INDOOR TRIGGERS FOR ASTHMA	SUGGESTIONS FOR REDUCING EXPOSURE
Viral upper respiratory tract (RSV, influenza virus)	Limit exposure to viral infections (day care with fewer children)
	Annual influenza immunization for children with persistent asthma
Tobacco smoke, wood smoke	No smoking around the child or in child's home
	Help parents and caregivers quit smoking
	Eliminate use of wood stoves and fireplaces
Dust mites	ESSENTIAL ACTIONS
	Encase pillow, mattress, and box spring in allergen-impermeable encasements
	Wash bedding in hot water weekly

1	1			
	DESIRABLE ACTIONS			
	Avoid sleeping or lying on upholstered furniture			
	Minimize number of stuffed toys in child's bedroom			
	Reduce indoor humidity to <50%			
	If possible, remove carpets from bedroom and play areas; if not possible, vacuum weekly			
nimal dander	Remove the pet from the home or keep outdoors (if removal is not acceptable)			
	Keep pet out of bedroom/no sleeping with pet			
	Use a filter on air ducts in child's room			
	Wash pet weekly (the evidence to support this has not been firmly established)			
Cockroach allergens	Do not leave food or garbage exposed			
	Pesticides			
	Sealing cracks and holes			
Indoor mold	Avoid vaporizers			
	Reduce indoor humidity to <50%			
	Use of mold inhibiting cleaner			
	Use of dehumidifier			
	Fix leaky faucets, pipes			
	· · · · · · · · · · · · · · · · · · ·			

#### Treatment

- includes several key components:
- environmental control,
- pharmacologic therapy,
- and patient education, including attainment of self-management skills.
- Because many children with asthma have coexisting allergies, steps to minimize allergen exposure should be taken
- For all children with asthma,
- exposures to tobacco and wood smoke and to should be minimized
- Influenza immunization is indicated.
- Asthma medications can be divided into long-term control medications and quick-relief medications.

- Inhaled corticosteroids are the most effective anti inflammatory medications for the treatment of chronic, persistent asthma and are the preferred therapy when initiating long-term control therapy
- :Low-to-medium dose inhaled corticosteroids may decrease growth velocity, although these effects are small (approximately 1 cm in the first year of treatment), Height measurements should be monitored.
- Inhaled corticosteroids do not have clinically significant adverse effects on hypothalamic-pituitary-adrenal axis function, glucose metabolism, subcapsular cataracts, or glaucoma when used at low-to-medium doses in children.
- Rinsing the mouth after inhalation and using large volume spacers help lessen the local adverse effects of dysphonia and candidiasis and decrease systemic absorption from the gastrointestinal tract.
- Inhaled corticosteroids should be titrated to the lowest dose needed to maintain control of a child's asthma.
- For children with severe asthma, high dose inhaled corticosteroids may be needed to minimize oral corticosteroid use, but other "add-on" therapy should be considered

- Leukotriene Modifiers are potent mediators of inflammation and smooth muscle bronchoconstriction.
- Two classes of leukotriene modifiers include cysteinyl leukotriene receptor antagonists (zafirlukast and montelukast) and leukotriene synthesis inhibitors (zileuton).
- Long-Acting  $\beta$ 2-Agonists: formoterol and salmeterol, have twice-daily dosing and relax airway smooth muscle for 12 hours but do not have any significant antiinflammatory effects.
- Adding a long-acting bronchodilator to inhaled corticosteroid therapy is more beneficial than doubling the dose of inhaled

- Theophylline (usage declined)
- It is mildly to moderately effective as a bronchodilator and is considered an alternative, add-on treatment to low- and medium-dose inhaled corticosteroids
- Quick-Relief Medications
- Short-Acting β2-Agonists: albuterol and levalbuterol are effective :relaxing bronchial smooth muscle within 5-10 minutes of administration.,
- ashort-acting β2-agonist is prescribed for acute symptoms and as prophylaxis before allergen exposure and exercise.
- Anticholinergic Agents Ipratropium bromide is a short-acting anticholinergic bronchodilator that relieves bronchoconstriction, decreases mucus hypersecretion, and counteracts cough receptor (additive effect with  $\beta$ 2-agonists) in asthma attack

- Oral Corticosteroids: Short bursts of oral corticosteroids (3-10 days)
  are administered to children with acute exacerbations. The usual dose
  is 1-2 mg/kg/day of prednisone for 5 days.
- Administration of two doses of dexamethasone for the treatment of acute asthma exacerbations has been used
- This oral corticosteroid has properties that may increase compliance with therapy

# Stepwise Approach to Therapy

- in 3 level of age :children 0-4 years of age, children 5-11 years of age and youths 12 years or older, and adults
- Medication type, dose, and dosing intervals are determined by the level of asthma severity or asthma control.
- Therapy is then increased (stepped up) as necessary and decreased (stepped down) when possible.
- using the Rules of Two is helpful: daytime symptoms occurring two or more times per week or nocturnal awakenings two or more times per month implies a need for daily anti inflammatory medication.

Intermittent asthma

Step 1

Preferred:

SABA PRN

#### Persistent asthma: Daily medication

Consult with asthma specialist if Step 4 care or higher is required. Consider consultation at Step 3.

Step 4

Medium-dose

ICS + LABA

Alternative:

Medium-dose



#### Step 6

Preferred:

Step 5

Preferred:

High-dose

ICS + LABA

AND

Consider

Omalizumab

for patients

who have

allergies

High-dose ICS + LABA + oral corticosteroid

AND

Consider Omalizumab for patients who have allergies

Step up if needed

(first, check adherence. environmental control, and comorbid conditions)

> Assess control

Step down if possible

(and asthma is well controlled at least 3 months)

#### Step 3 Preferred:

Preferred: Low-dose

ICS + LABA OR Medium-dose

Alternative:

Low-dose ICS + either LTRA.

ICS + either ICS LTRA. Theophylline. or Zileuton Theophylline, or Zileuton

#### Each step: Patient education, environmental control, and management of comorbidities.

Steps 2-4. Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see Notes).

#### Quick-relief medication for all patients

Step 2

Low-dose ICS

Alternative:

Cromolyn.

Nedocromil,

Theophylline

LTRA.


Preferred:

- . SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed. Short course of oral systemic conficosteroids may be needed.
- Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment.

	Low Daily Dose			Me	edium Daily D	ose	High Daily Dose		
Drug	Child 0-4 Years of Age	Child 5-11 Years of Age	≥12 Years of Age and Adults	Child 0-4 Years of Age	Child 5-11 Years of Age	≥12 Years of Age and Adults	Child 0-4 Years of Age	Child 5-11 Years of Age	≥12 Years of Age and Adults
Beclomethasone HFA 40 or 80 µg/pulf	NA	80-160 µg	80-240 µg	NA	>160-320 µg	>240~480 µg	NA	>320 µg	>480 µg
Budesonide DPI 90, 180, or 200 µg/inhalation	NA	180-400 µg	180-600 µg	NA.	>400-800 µg	>600-1,200 µg	NA	>800 µg	s1,200 µg
Budesonide Inheled Inhalation suspension for nebulization	0.25-0.5 mg	0.5 mg	NA	>0.5-1.0 mg	1,0 mg	NA	>1.0 mg	2.0 mg	NA
Flunisolide 250 µg/puff	NA	500-750 µg	500-1,000 µg	NA	1,000-1,250 µg	>1,000-2,000 µg	NA	>1,250 µg	>2,000 µg
Flunisolide HFA 80 µg/puff	NA	160 µg	320 µg	NA	320 µg	>320-640 µg	NA	≥640 µg	>640 µg
Fluticasone HFA/MDI: 44, 110, or 220 µg/putt DPI: 50, 100, or	176 µg NA	88-176 µg 100-200 µg	88-264 µg 100-300 µg	>176-352 µg NA	>176-352 µg >200-400 µg	>264-440 µg >300-500 µg	>352 µg	>352 µg >400 µg	>440 µg >500 µg
250 µg/inhalation Mometasone DPI 200 µg/inhalation	NA	NA.	200 µg	NA .	NA.	400 µg	NA	NA	>400 µg
Friamcinolone acetonide 75 µg/puff	NA	300-600 µg	300-750 µg	NA .	>600-900 µg	>750-1,500 µg	NA .	>900 µg	>1,500 µg

- Inhaled corticosteroids are the preferred initial long-term control therapy for children of all ages
- Daily long-term control therapy is recommended for infants and young children 0-4 years of age who had four or more episodes of wheezing in the previous year that lasted more than 1 day, affected sleep, and who have a positive asthma predictive index
- For children over 5 years of age: with moderate persistent asthma, combining long-acting bronchodilators with low-to-medium doses of inhaled corticosteroids improves lung function and reduces rescue medication use.
- For children with severe persistent asthma, a high-dose inhaled corticosteroid combined with a long-acting bronchodilator is the preferred therapy.
- Reevaluation within 4-6 weeks when the asthma is well controlled for at least 3 months ➤ stepping down

#### Initial assessment Brief history, physical examination (auscultation, use of accessory muscles, heart rate, respiratory rate), PEF or FEV<sub>1</sub>, oxygen saturation, and other tests as indicated FEV<sub>1</sub> or PEF ≥40% (mild-to-moderate) FEV, or PEF <40% (severe) Impending or actual respiratory Oxygen to achieve SaO₂ ≥90% Oxygen to achieve SaO₂ ≥90% arrest · High-dose inhaled SABA plus Intubation and mechanical Inhaled SABA by nebulizer or MDI with valved holding chamber, up to Ipratropium by nebulizer or MDI ventilation with 100% oxygen 3 doses in first hour plus valved holding chamber, Nebulized SABA and Ipratropium every 20 minutes or continuously · Oral systemic corticosteroids if no Intravenous corticosteroids immediate response or if patient Consider adjunct therapies for 1 hour recently took oral systemic Oral systemic corticosteroids corticosteroids Admit to hospital intensive care Repeat assessment (see box below) Symptoms, physical examination, PEF, O2 saturation, other tests as needed Moderate exacerbation Severe exacerbation FEV<sub>1</sub> or PEF 40-69% predicted/personal best FEV<sub>1</sub> or PEF <40% predicted/personal best Physical exam: moderate symptoms Physical exam: severe symptoms at rest, accessory muscle Inhaled SABA every 60 minutes use, chest retraction Oral systemic corticosteroid History: high-risk patient · Continue treatment 1-3 hours, provided No improvement after initial treatment there is improvement; make admit Oxygen decision in <4 hours Nebulized SABA plus Ipratropium, hourly or continuous Oral systemic corticosteroids Consider adjunct therapies



# Complications

- Most asthma exacerbations can be successfully managed at home.
- Status asthmaticus is an acute exacerbation of asthma that does not respond adequately to therapeutic measures and may require hospitalization.
- Exacerbations may progress over several days or occur suddenly and can range in severity from mild to life threatening.
- Significant respiratory distress, dyspnea, wheezing, cough, and a decrease in spirometry or peak expiratory flow rate (PEFR) characterize deterioration in asthma control.
- During a severe episode pulse oximetry is helpful in monitoring oxygenation. In status asthmaticus, arterial blood gases may be necessary for measurement of ventilation.
- As airway obstruction worsens and chest compliance decreases, carbon dioxide retentioncan occur.
- In tachypnea, a normal PCO2 (35-45 mm Hg) indicates impending respiratory arrest

### management of asthma exacerbations

- First-line includes supplemental oxygen
- if needed and repetitive or continuous administration of short-acting bronchodilators.
- Early administration of oral or intravenous corticosteroids is important in treating the underlying inflammation.
- Administration of anticholinergic agents (ipratropium) with bronchodilators decreases rates of hospitalization and duration of time in the emergency department.
- Intravenous magnesium sulfate is administered in the emergency department if there is clinical deterioration despite treatment with β2-agonists, ipratropium, and systemic corticosteroids.
- The typical dose of magnesium sulfate is 25-75 mg/kg (maximum 2.0 g) intravenously administered over 20 minutes.
- Intramuscular epinephrine or subcutaneous terbutaline are rarely used except when severeasthma is associated with anaphylaxis or unresponsive to continuous administration of short-acting bronchodilators.

### Prognosis

- For some children, symptoms of wheezing with respiratory infections subside in the preschool years, whereas others have more persistent asth ma symptoms.
- Prognostic indicators for children younger than 3 years of age who are at risk forpersistent asthma are known as the Modified Asthma
   Predictive Index for children
- Atopy is the strongest predictor for wheezing continuing into persistent asthma

#### **Modified Asthma Predictive Index for Children**

At least four wheezing episodes plus:		
1 Major criteria	Or 2 Minor criteria	
Parental asthma	Allergic rhinitis	
Eczema	Wheezing apart from colds	
Inhalant allergen sensitization	Eosinophils ≥ 4%	
	Food allergen sensitization	

#### **Risk Factors for Persistent Asthma**

Allergy	Atopic dermatitis		
	Allergic rhinitis		
	Elevated total serum IgE levels (first year of life)		
	Peripheral blood eosinophilia >4% (2-3 yr of age)		
	Inhalant and food allergen sensitization		
Gender	Males		
	Transient wheezing		
	Persistent allergy-associated asthma		
	Females		
	Asthma associated with obesity and early-onset puberty		
	• "Triad" asthma (adulthood)		
Parental asthma			
Lower respiratory tract infections	Rhinovirus, respiratory syncytial virus		
	Severe bronchiolitis (i.e., requiring hospitalization)		
	Pneumonia		
Environmental tobacco smoke exposure (including prenatal)			

### Prevention

- Education plays an important role in helping patients and their families adhere to therapy
- Successful education :
- teaching basic asthma facts,
- explaining the role of medications,
- teaching environmental control measures,
- and improving patient skills in the use of spacer devices for metered dose inhalers and peak flow monitoring.
- Families should have an asthma management plan for daily care and for exacerbations.

or	Doctor:		Date:		
octor's Phone Number	Hospital/Emergency Depar	Hospital/Emergency Department Phone Number			
Doing Well  No cough, wheeze, chest tightness, or shortness of breath during the day or night.  Can do usual activities	Take these long-term-control me Medicine	How much to take	nti-inflammatory). When to take it		
And, if a peak flow meter is used, Peak flow: more than   (80 percent or more of my best peak flow)	Identify and avoid and control the things that make your asthma worse, like (list here):				
My best peak flow is:	Betore exercise, if prescribed, take:	□2 or □4 puffs	5 to 60 minutes before exercise		
Asthma Is Getting Worse  Cough, wheeze, chest tightness, or shortness of breath, or Waking at night due to asthma, or Can do some, but not all, usual activities  Or-  Peak flow:  (50 to 79 percent of my best peak flow)	If applicable, remove yours If your symptoms (and pea  Continue monitoring Or- If your symptoms (and pea	self from the thing that made you ik flow, if used) return to GREEN to be sure you stay in the green ik flow, if used) do not return to ( icting beta <sub>2</sub> -agonist) if corticosteroid)	ffs, every 20 minutes for up to 1 hour noce in asthma worse. I ZONE after 1 hour of above treatment: zone.  GREEN ZONE after 1 hour of above treatment:		
Very short of breath, or     Quick-relief medicines have not helped, or     Gannot do usual activities, or     Symptoms are same or get worse after     24 hours in Yellow Zone.	Take this medicine:  (short-acting beta <sub>2</sub> -ago (oral corticosteroid)  Then call your doctor NOW. Go to You are still in the red zone after the control of th	to the hospital or call an ambular ter 15 minutes AND			

(phone)